AU2003281287A8 - Toxicity markers - Google Patents

Toxicity markers

Info

Publication number
AU2003281287A8
AU2003281287A8 AU2003281287A AU2003281287A AU2003281287A8 AU 2003281287 A8 AU2003281287 A8 AU 2003281287A8 AU 2003281287 A AU2003281287 A AU 2003281287A AU 2003281287 A AU2003281287 A AU 2003281287A AU 2003281287 A8 AU2003281287 A8 AU 2003281287A8
Authority
AU
Australia
Prior art keywords
toxicity markers
markers
toxicity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003281287A
Other versions
AU2003281287A1 (en
Inventor
Lasantha Ranasinghe-Bandara
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford Glycosciences UK Ltd
Original Assignee
Oxford Glycosciences UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0215575A external-priority patent/GB0215575D0/en
Priority claimed from GB0220879A external-priority patent/GB0220879D0/en
Application filed by Oxford Glycosciences UK Ltd filed Critical Oxford Glycosciences UK Ltd
Publication of AU2003281287A8 publication Critical patent/AU2003281287A8/en
Publication of AU2003281287A1 publication Critical patent/AU2003281287A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2003281287A 2002-07-04 2003-07-04 Toxicity markers Abandoned AU2003281287A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0215575A GB0215575D0 (en) 2002-07-04 2002-07-04 Toxicity marker
GB0215575.2 2002-07-04
GB0220879A GB0220879D0 (en) 2002-09-09 2002-09-09 Toxicity markers
GB0220879.1 2002-09-09
PCT/GB2003/002893 WO2004005934A2 (en) 2002-07-04 2003-07-04 Toxicity markers

Publications (2)

Publication Number Publication Date
AU2003281287A8 true AU2003281287A8 (en) 2004-01-23
AU2003281287A1 AU2003281287A1 (en) 2004-01-23

Family

ID=30117095

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003281287A Abandoned AU2003281287A1 (en) 2002-07-04 2003-07-04 Toxicity markers

Country Status (2)

Country Link
AU (1) AU2003281287A1 (en)
WO (1) WO2004005934A2 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006291990B2 (en) 2005-09-13 2012-05-31 National Research Council Of Canada Methods and compositions for modulating tumor cell activity
DK2125899T3 (en) 2007-03-26 2013-02-11 Novartis Ag Biomarkers for predicting renal safety as well as biomarker signatures for monitoring renal function
US8575107B2 (en) * 2008-01-22 2013-11-05 Compugen Ltd. Clusterin derived peptide
EP2324355B1 (en) 2008-08-28 2014-01-22 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2010025434A1 (en) 2008-08-29 2010-03-04 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CN103760359B (en) 2008-10-21 2017-01-11 阿斯图特医药公司 Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CN102264230B (en) 2008-11-10 2014-12-10 阿斯图特医药公司 Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US9229010B2 (en) 2009-02-06 2016-01-05 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ598034A (en) 2009-08-07 2014-06-27 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
AU2010315008B2 (en) 2009-11-07 2015-12-03 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CN102666585B (en) 2009-11-24 2015-02-18 阿莱斯亚生物疗法股份有限公司 Anti-clusterin antibodies and antigen binding fragments and their use to reduce tumor volume
WO2011075744A1 (en) 2009-12-20 2011-06-23 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
JP6199558B2 (en) 2009-12-23 2017-09-20 ヒルズ・ペット・ニュートリシャン・インコーポレーテッド Compositions and methods for diagnosing and treating renal injury in dogs
SI2666872T1 (en) 2010-02-05 2016-08-31 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
AU2011269847A1 (en) 2010-02-26 2013-01-31 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CA2790785A1 (en) 2010-02-26 2011-09-01 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CA2804297A1 (en) 2010-06-23 2011-12-29 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
ES2590263T3 (en) 2011-02-24 2016-11-21 Hill's Pet Nutrition, Inc. Compositions and methods for the diagnosis of renal disorders in a feline
WO2013086359A1 (en) 2011-12-08 2013-06-13 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2013123588A1 (en) 2012-02-22 2013-08-29 Alethia Biotherapeutics Inc. Co-use of a clusterin inhibitor with an egfr inhibitor to treat cancer
ES2681955T3 (en) 2013-01-17 2018-09-17 Astute Medical, Inc. Methods and compositions for the diagnosis and prognosis of renal injury and renal insufficiency
WO2014113712A1 (en) * 2013-01-20 2014-07-24 Dyax Corp. Evaluation and treatment of bradykinin-mediated disorders
EP3129781A4 (en) 2014-04-09 2017-10-11 The Regents of The University of California Protein biomarkers for immune assessment and prediction of transplant rejection
JP6948265B2 (en) * 2015-04-30 2021-10-13 アイデックス ラボラトリーズ インコーポレイテッドＩＤＥＸＸ Ｌａｂｏｒａｔｏｒｉｅｓ， Ｉｎｃ． Specific detection of crusterin isoforms
EP3316159A4 (en) 2015-06-25 2019-08-14 Advanced Telecommunications Research Institute International Prediction device based on multiple organ-related system and prediction program
EP3438282A4 (en) * 2016-03-29 2020-05-06 Advanced Telecommunications Research Institute International Screening method for candidate substances for active component to prevent or treat at least one disease selected from the group consisting of renal hypofunction, chronic kidney disease and kidney failure
WO2017170803A1 (en) * 2016-03-29 2017-10-05 株式会社国際電気通信基礎技術研究所 Pharmaceutical composition or food composition, and method for assessing effect of active ingredient in vivo
WO2017214203A1 (en) 2016-06-06 2017-12-14 Astute Medical, Inc. Management of acute kidney injury using insulin-like growth factor-binding protein 7 and tissue inhibitor of metalloproteinase 2

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1405072A2 (en) * 2000-12-29 2004-04-07 Oxford GlycoSciences (UK) Limited Proteins, genes and their use for diagnosis and treatment of kidney response
WO2003019193A1 (en) * 2001-08-30 2003-03-06 Ciphergen Biosystems, Inc. Method of diagnosing nephrotic syndrome

Also Published As

Publication number Publication date
WO2004005934A2 (en) 2004-01-15
AU2003281287A1 (en) 2004-01-23
WO2004005934A3 (en) 2004-08-26

Similar Documents

Publication Publication Date Title
AU2003281287A8 (en) Toxicity markers
GB0212855D0 (en) Paintball markers
AU2003301443A8 (en) Azolecarboxamide herbicides
PL371526A1 (en) Phosphorus-containing compounds and uses thereof
IL163652A0 (en) Substituted hydroxyethylamines
AU2003275645A8 (en) Luminescents
IL166740A0 (en) Substituted heterocyclylpyrimidines
GB2384292B (en) Paintball markers
GB2373311B (en) Paintball markers
PT1487778E (en) Substituted 4-aminocyclohexanols
AU152403S (en) Faceshield attachment
GB0225360D0 (en) Genetic markers
GB0200721D0 (en) Toxicity test
GB0307643D0 (en) Markers
GB0317231D0 (en) Tranquilliser darts
GB0307640D0 (en) Markers
GB0220879D0 (en) Toxicity markers
PL377325A1 (en) Substituted benzodioxepins
GB0215575D0 (en) Toxicity marker
GB0215577D0 (en) Toxicity marker
GB0102480D0 (en) Marker
GB0210260D0 (en) Pesticides
AU2003218924A1 (en) Luminescent markers
GB2385804B (en) Darts
GB0303728D0 (en) Toxicity marker

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase